Dasatinib is a multi-kinase inhibitor with potent activity against BCR–ABL kinase (IC₅₀ <1 nM) and Src family kinases (IC₅₀ = 0.2–1.1 nM). Dasatinib also inhibits Lyn (IC₅₀ = 8.5 nM) and Src (IC₅₀ = 3.0 nM) kinase activities in vitro using 0.1 mg/mL poly (Glu4-Tyr) as the substrate.